We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Solving POC Test Communication Challenges to EMRs

By LabMedica International staff writers
Posted on 02 Dec 2009
According to a leading healthcare market research publisher, a key question users of glucose monitors and other point-of-care (POC) tests may ask is "does the POC test talk to the user's electronic medical record (EMR).” As wireless communication becomes standard in hospitals, it is incumbent on the US$13 billion worldwide market for POC test systems to participate fully in this phenomenon. More...


Connectivity is a high priority issue in order for hospital POC testing and critical care device markets to expand, according to the findings of a recent market report from healthcare market research publisher Kalorama Information (New York, NY, USA). "On-the-spot access to patient information and care guidelines is part of the healthcare quality imperative of the 21st century,” noted Shara Rosen, Kalorama Information's diagnostics analyst. "Cost reduction pressures and the need for shortened in-patient stays are promoting the use of wireless communication in and out of hospitals.”

While the worldwide medical community is racing to embrace EMR and telemedicine, most POC test devices currently have limited connectivity capabilities and cannot participate. At this time, all major lab-based instruments interface automatically to a laboratory information system (LIS) or hospital information system (HIS) system. However, many glucose monitors in hospital wards do not have this connectivity capability and so they do not become part of a patient's EMR. The same applies to almost all pregnancy and urinalysis tests performed in the hospital but outside the laboratory.

Within today's hospital environment of limited resources, cost pressures, decentralized patient information, large investment in new technologies and increased regulatory scrutiny, healthcare is more challenging than ever before. POC testing is poised to provide a solution to some of these economic pressures. However, without first-class connectivity solutions, POC testing cannot provide the expected benefits in improved patient care that will lead to cost reductions. "Any manufacturers who want to make their POC products incredibly valuable should make sure they can link up with major EMR systems,” said Ms. Rosen.

Beyond the connectivity issue, the next frontier is continuous monitoring of patients in acute care and in selected treatment areas such as dialysis, intensive care, and the operating room (OR). Moreover, as the number of POC tests continues to grow, potential users will not want to learn to use a large number of devices. Therefore, considerable research has been ongoing for about a decade on a multipurpose POC platform that can run chemistries and immunoassays.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Kalorama Information


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.